We believe our commitment to the Triple Bottom Line -- social responsibility, environmental soundness, and economic viability -- makes good business sense, so we have made it a top strategic priority. We take this philosophy one step further by producing an annual environmental and social report that accounts for the ways in which these values are put into practice within the Novo Group.
At Novo Nordisk, we take all our commitments very seriously, especially our commitment to people. We also take particular interest in the preservation and restoration of the global environment. We want to minimize the ecological impact of our operations by developing more processes that reduce emissions and the consumption of energy and raw materials.
Social: We will work to continuously improve our social performance by setting high objectives and integrating social, human rights and health and safety considerations into our daily business. We will maintain an open dialogue with our stakeholders and report annually on our social performance.
Novo Nordisk supports the United Nations Universal Declaration of Human Rights.
We offer a patient assistance program to help people who do not have private health insurance and who do not qualify for private, local, state, or federal prescription reimbursement. Individuals who fall into these categories can contact Novo Nordisk directly about the program.
Environmental: We will work to continuously improve our environmental performance by setting high objectives and integrating environmental and bioethical considerations into our daily business. We will maintain an open dialogue with our stakeholders and report annually on our environmental performance.
We will subscribe to the International Chamber of Commerce's Business Charter for Sustainable Development.
Novo Nordisk supports the United Nations Convention on biological diversity.
Financial: We will work to continuously improve our financial performance by setting high objectives for growth and value creation, and deliver competitive performance in these areas. We will maintain an open dialogue with our stakeholders and comply with international reporting standards.
Headquartered in Denmark, Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy, and hormone replacement therapy.
Stock info (NYSE quotes delayed by 15 minutes. Currency in USD)